Skip to main content

Table 3 Further subgroup analysis and sensitivity analyses on primary outcome of gastrointestinal bleeding rate

From: Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis

  Studies, number Patients, number Event in SUP group Event in control group Risk ratio (95% CI) I 2 p
Subgroup analyses
 Type of SUP PPI 4 527 8 of 270 16 of 257 0.49 (0.21, 1.10) 4% 0.08
H2RA 3 262 20 of 130 13 of 132 1.60 (0.86, 3.05) 16% 0.15
Sucralfate 1 200 5 of 100 6 of 100 0.83 (0.26, 2.64) - 0.76
 Published year After 2000 4 527 8 of 270 16 of 257 0.49 (0.21, 1.10) 4% 0.08
Before 2000 3 362 20 of 230 13 of 132 0.75 (0.30, 1.86) 0% 0.53
 Sample size <100 3 153 14 of 79 10 of 74 1.42 (0.68, 2.94) 12% 0.35
>100 4 736 14 of 421 19 of 315 0.52 (0.26, 1.04) 0% 0.07
 Study designed Blinded 4 435 13 of 224 11 of 211 1.12 (0.52, 2.44) 0% 0.77
Unblinded 3 454 15 of 276 18 of 178 0.62 (0.32, 1.19) 35% 0.15
 Setting MICU 3 436 16 of 271 13 of 165 0.87 (0.44, 1.73) 0% 0.70
Mixed ICU 4 453 12 of 229 16 of 224 0.73 (0.36, 1.50) 0% 0.73
 Administration route Oral 2 669 23 of 340 23 of 329 1.0 (0.58, 1.72) 0% 1.00
Intravenous 6 320 5 of 160 12 of 160 0.35 (0.03, 3.84) 62% 0.39
Sensitivity analyses
 GI bleeding Overt GI bleeding 6 589 18 of 300 23 of 289 0.79 (0.44, 1.39) 24% 0.41
Clinical important GI bleeding 4 725 13 of 415 13 of 310 0.63 (0.29, 1.37) 25% 0.25
Randomized-effects models 7 889 28 of 500 29 of 389 0.87 (0.50, 1.53) 8% 0.63
Early enteral nutrition 6 798 24 of 451 26 of 347 0.76 (0.49, 1.29) 22% 0.31
  1. CIB clinical important bleeding, SUP stress ulcer prophylaxis, H 2 RA histamine 2 receptor antagonist, GI gastrointestinal, MICU medical intensive care unit, Mixed medical-surgical intensive care unit, PPI proton pump inhibitor